Schildgen 2020 [C].
Study characteristics | |||
Patient Sampling | Comparative study of three Ag tests; Schildgen 2020 [A] reports full study characteristics and QUADAS | ||
Patient characteristics and setting | Comparative study of three Ag tests; Schildgen 2020 [A] reports full study characteristics and QUADAS | ||
Index tests | Comparative study of three Ag tests (no product codes reported); Schildgen 2020 [C] data relate to test [C], see Schildgen 2020 [A] and Schildgen 2020 [B] for data relate to tests [A] and [B], and for QUADAS entries. Test name: [A] BIOCREDIT [B] Panbio [C] SARS‐CoV‐2 Rapid Antigen test Manufacturer: [A] RapiGEN [B] Abbott [C] Roche Antibody: Not stated Antigen target: Not stated Test method: All LFA Samples used: BAL (n=13); throat wash (n=50, including 27 from asymptomatic) Transport media: Not stated Sample storage: Not stated Test operator: Not stated; presume lab staff Definition of test positivity: As per manufacturer Blinding reported: Not stated Timing of samples: Not stated |
||
Target condition and reference standard(s) | Comparative study of three Ag tests; Schildgen 2020 [A] reports full study characteristics and QUADAS | ||
Flow and timing | Comparative study of three Ag tests; Schildgen 2020 [A] reports full study characteristics and QUADAS | ||
Comparative | |||
Notes |